Statistical Methods in Medical Research最新文献

Individualized treatment rules inform tailored treatment decisions based on the patient's information, where the goal is to optimize clinical benefit for the population. When the clinical outcome of interest is survival time, most of current approaches typically aim to maximize the expected time of survival. We propose a new criterion for constructing Individualized treatment rules that optimize the clinical benefit with survival outcomes, termed as the adjusted probability of a longer survival. This objective captures the likelihood of living longer with being on treatment, compared to the alternative, which provides an alternative and often straightforward interpretation to communicate with clinicians and patients. We view it as an alternative to the survival analysis standard of the hazard ratio and the increasingly used restricted mean survival time. We develop a new method to construct the optimal Individualized treatment rule by maximizing a nonparametric estimator of the adjusted probability of a longer survival for a decision rule. Simulation studies demonstrate the reliability of the proposed method across a range of different scenarios. We further perform data analysis using data collected from a randomized Phase III clinical trial (SWOG S0819).

A useful parametric specification for the expected value of an epidemiological process is revived, and its statistical and empirical efficacy are explored. The Richards' curve is flexible enough to adapt to several growth phenomena, including recent epidemics and outbreaks. Here, two different estimation methods are described. The first, based on likelihood maximisation, is particularly useful when the outbreak is still ongoing and the main goal is to obtain sufficiently accurate estimates in negligible computational run-time. The second is fully Bayesian and allows for more ambitious modelling attempts such as the inclusion of spatial and temporal dependence, but it requires more data and computational resources. Regardless of the estimation approach, the Richards' specification properly characterises the main features of any growth process (e.g. growth rate, peak phase etc.), leading to a reasonable fit and providing good short- to medium-term predictions. To demonstrate such flexibility, we show different applications using publicly available data on recent epidemics where the data collection processes and transmission patterns are extremely heterogeneous, as well as benchmark datasets widely used in the literature as illustrative.

For personalized medicine, we propose a general method of evaluating the potential performance of an individualized treatment rule in future clinical applications with new patients. We focus on rules that choose the most beneficial treatment for the patient out of two active (nonplacebo) treatments, which the clinician will prescribe regularly to the patient after the decision. We develop a measure of the individualization potential (IP) of a rule. The IP compares the expected effectiveness of the rule in a future clinical individualization setting versus the effectiveness of not trying individualization. We illustrate our evaluation method by explaining how to measure the IP of a useful type of individualized rules calculated through a new parametric interaction model of data from parallel-group clinical trials with continuous responses. Our interaction model implies a structural equation model we use to estimate the rule and its IP. We examine the IP both theoretically and with simulations when the estimated individualized rule is put into practice in new patients. Our individualization approach was superior to outcome-weighted machine learning according to simulations. We also show connections with crossover and N-of-1 trials. As a real data application, we estimate a rule for the individualization of treatments for diabetic macular edema and evaluate its IP.

Cluster randomized crossover and stepped wedge cluster randomized trials are two types of longitudinal cluster randomized trials that leverage both the within- and between-cluster comparisons to estimate the treatment effect and are increasingly used in healthcare delivery and implementation science research. While the variance expressions of estimated treatment effect have been previously developed from the method of generalized estimating equations for analyzing cluster randomized crossover trials and stepped wedge cluster randomized trials, little guidance has been provided for optimal designs to ensure maximum efficiency. Here, an optimal design refers to the combination of optimal cluster-period size and optimal number of clusters that provide the smallest variance of the treatment effect estimator or maximum efficiency under a fixed total budget. In this work, we develop optimal designs for multiple-period cluster randomized crossover trials and stepped wedge cluster randomized trials with continuous outcomes, including both closed-cohort and repeated cross-sectional sampling schemes. Local optimal design algorithms are proposed when the correlation parameters in the working correlation structure are known. MaxiMin optimal design algorithms are proposed when the exact values are unavailable, but investigators may specify a range of correlation values. The closed-form formulae of local optimal design and MaxiMin optimal design are derived for multiple-period cluster randomized crossover trials, where the cluster-period size and number of clusters are decimal. The decimal estimates from closed-form formulae can then be used to investigate the performances of integer estimates from local optimal design and MaxiMin optimal design algorithms. One unique contribution from this work, compared to the previous optimal design research, is that we adopt constrained optimization techniques to obtain integer estimates under the MaxiMin optimal design. To assist practical implementation, we also develop four SAS macros to find local optimal designs and MaxiMin optimal designs.

Prognostic biomarkers for survival outcomes are widely used in clinical research and practice. Such biomarkers are often evaluated using a C-index as well as quantities based on time-dependent receiver operating characteristic curves. Existing methods for their evaluation generally assume that censoring is uninformative in the sense that the censoring time is independent of the failure time with or without conditioning on the biomarker under evaluation. With focus on the C-index and the area under a particular receiver operating characteristic curve, we describe and compare three estimation methods that account for informative censoring based on observed baseline covariates. Two of them are straightforward extensions of existing plug-in and inverse probability weighting methods for uninformative censoring. By appealing to semiparametric theory, we also develop a doubly robust, locally efficient method that is more robust than the plug-in and inverse probability weighting methods and typically more efficient than the inverse probability weighting method. The methods are evaluated and compared in a simulation study, and applied to real data from studies of breast cancer and heart failure.

Bounded count response data arise naturally in health applications. In general, the well-known beta-binomial regression model form the basis for analyzing this data, specially when we have overdispersed data. Little attention, however, has been given to the literature on the possibility of having extreme observations and overdispersed data. We propose in this work an extension of the beta-binomial regression model, named the beta-2-binomial regression model, which provides a rather flexible approach for fitting a regression model with a wide spectrum of bounded count response data sets under the presence of overdispersion, outliers, or excess of extreme observations. This distribution possesses more skewness and kurtosis than the beta-binomial model but preserves the same mean and variance form of the beta-binomial model. Additional properties of the beta-2-binomial distribution are derived including its behavior on the limits of its parametric space. A penalized maximum likelihood approach is considered to estimate parameters of this model and a residual analysis is included to assess departures from model assumptions as well as to detect outlier observations. Simulation studies, considering the robustness to outliers, are presented confirming that the beta-2-binomial regression model is a better robust alternative, in comparison with the binomial and beta-binomial regression models. We also found that the beta-2-binomial regression model outperformed the binomial and beta-binomial regression models in our applications of predicting liver cancer development in mice and the number of inappropriate days a patient spent in a hospital.

The mixture of probabilistic regression models is one of the most common techniques to incorporate the information of covariates into learning of the population heterogeneity. Despite its flexibility, unreliable estimates can occur due to multicollinearity among covariates. In this paper, we develop Liu-type shrinkage methods through an unsupervised learning approach to estimate the model coefficients in the presence of multicollinearity. We evaluate the performance of our proposed methods via classification and stochastic versions of the expectation-maximization algorithm. We show using numerical simulations that the proposed methods outperform their Ridge and maximum likelihood counterparts. Finally, we apply our methods to analyze the bone mineral data of women aged 50 and older.

Estimation of the 100p percent lethal dose (${\text{LD}}_{100p}$) is of great interest to pharmacologists for assessing the toxicity of certain compounds. However, most existing literature focuses on the interval estimation of ${\text{LD}}_{100p}$ and little attention has been paid to its point estimation. Currently, the most commonly used method for estimating the ${\text{LD}}_{100p}$ is the maximum likelihood estimator (MLE), which can be represented as a ratio estimator, with the denominator being the slope estimated from the logistic regression model. However, the MLE can be seriously biased when the sample size is small, a common nature in such studies, or when the dose-response curve is relatively flat (i.e. the slope approaches zero). In this study, we address these issues by developing a novel penalised maximum likelihood estimator (PMLE) that can prevent the denominator of the ratio from being close to zero. Similar to the MLE, the PMLE is computationally simple and thus can be conveniently used in practice. Moreover, with a suitable penalty parameter, we show that the PMLE can (a) reduce the bias to the second order with respect to the sample size and (b) avoid extreme estimates. Through simulation studies and real data applications, we show that the PMLE generally outperforms the existing methods in terms of bias and root mean square error.

This study investigates the heterogeneity of a biomarker's discriminative performance for predicting subsequent time-to-event outcomes across different patient subgroups. While the area under the curve (AUC) for the time-dependent receiver operating characteristic curve is commonly used to assess biomarker performance, the partial time-dependent AUC (PAUC) provides insights that are often more pertinent for population screening and diagnostic testing. To achieve this objective, we propose a regression model tailored for PAUC and develop two distinct estimation procedures for discrete and continuous covariates, employing a pseudo-partial likelihood method. Simulation studies are conducted to assess the performance of these procedures across various scenarios. We apply our model and inference procedure to the Alzheimer's Disease Neuroimaging Initiative data set to evaluate potential heterogeneities in the discriminative performance of biomarkers for early Alzheimer's disease diagnosis based on patients' characteristics.